"Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Anti-Neoplastic Ag" by Daniel Lexcen, Ahmed H. Salem et al.
 

Files

Download

Download Full Text (349 KB)

Description

"Development of tumor resistance to chemotherapeutics is related to inherent tumor variations regarding sensitivity to chemotherapeutics and to sub-optimal dosing regimens, including variation in patient pharmacokinetics that result in suboptimal exposure of tumor cells to anti-neoplastic drugs [1, 2]. The rate and extent of drug efficacy depends on the extent of drug exposure at the tumor site and the time above the effective concentration [3]. In vitro models that incorporate these pharmacokinetic and pharmacodynamic (PK/PD) principles to optimize therapeutic response may be considered the method of choice for optimizing dosing schedules before translating data from static assays to animals and clinical trials [4, 5]. The hollow fiber bioreactor was recently used to evaluate pharmacokinetic/pharmacodynamic (PK/PD) effects of gemcitibine in lung and breast cancers and to model HIV treatments [4-6]."

ISBN

978-953-51-0533-6

Publication Date

4-20-2012

Publisher

InTech

City

Rijeka, Croatia

Keywords

tumor resistance, chemotherapeutics, dosing regimens, pharmacokinetics, pharmacodynamics, PK/PD

Disciplines

Medicinal and Pharmaceutical Chemistry | Oncology | Other Chemicals and Drugs | Other Pharmacy and Pharmaceutical Sciences | Pharmaceutical Preparations | Pharmaceutics and Drug Design

Comments

In Ayman M. Noreddin (Ed.), Readings in Advanced Pharmacokinetics - Theory, Methods and Applications. Dr. Noreddin's chapter begins on page 315.

Copyright

The authors

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Anti-Neoplastic Agents

Share

COinS